Histrelin information

Histrelin
Clinical data
Trade names	Vantas, Supprelin LA, others
AHFS/Drugs.com	Monograph
MedlinePlus	a601146
Routes of; administration	Subcutaneous implant
Drug class	GnRH analogue; GnRH agonist; Antigonadotropin
ATC code	L02AE05 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	92%
Protein binding	70%
Metabolism	Hepatic
Elimination half-life	4.0 hours
Identifiers
	IUPAC name 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-1-benzyl-D-histidyl-L-leucyl-N5-(diaminomethylene)-L-ornithyl-N-ethyl-L-prolinamide;
CAS Number	76712-82-8 ;
PubChem CID	25077993;
IUPHAR/BPS	3884;
ChemSpider	10482012 ;
UNII	H50H3S3W74;
KEGG	D02369 ;
ChEMBL	ChEMBL1201255 ;
CompTox Dashboard (EPA)	DTXSID50227543 ;
ECHA InfoCard	100.163.860
Chemical and physical data
Formula	C66H86N18O12
Molar mass	1323.528 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1cn(Cc2ccccc2)cn1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1;
	InChI InChI=1S/C66H86N18O12/c1-4-70-64(95)55-17-11-25-84(55)65(96)48(16-10-24-71-66(67)68)76-58(89)49(26-38(2)3)77-62(93)53(30-43-34-83(37-74-43)33-40-12-6-5-7-13-40)81-59(90)50(27-39-18-20-44(86)21-19-39)78-63(94)54(35-85)82-60(91)51(28-41-31-72-46-15-9-8-14-45(41)46)79-61(92)52(29-42-32-69-36-73-42)80-57(88)47-22-23-56(87)75-47/h5-9,12-15,18-21,31-32,34,36-38,47-55,72,85-86H,4,10-11,16-17,22-30,33,35H2,1-3H3,(H,69,73)(H,70,95)(H,75,87)(H,76,89)(H,77,93)(H,78,94)(H,79,92)(H,80,88)(H,81,90)(H,82,91)(H4,67,68,71)/t47-,48-,49-,50-,51-,52-,53+,54-,55-/m0/s1 ; Key:HHXHVIJIIXKSOE-QILQGKCVSA-N ;
	(what is this?) (verify)

Histrelin acetate, sold under the brand names Vantas and Supprelin LA among others, is a nonapeptide analogue of gonadotropin-releasing hormone (GnRH) with added potency.^[1] When present in the bloodstream, it acts on particular cells of the pituitary gland called gonadotropes. Histrelin stimulates these cells to release luteinizing hormone and follicle-stimulating hormone. Thus it is considered a gonadotropin-releasing hormone agonist or GnRH agonist.

^ Davis M (25 February 2005). Chandramouli J (ed.). "Histrelin acetate (Vantas)". New Drug Bulletins. University of Utah Hospitals & Clinics. Archived from the original on 10 May 2006.

[def-1] Davis M (25 February 2005). Chandramouli J (ed.). "Histrelin acetate (Vantas)". New Drug Bulletins. University of Utah Hospitals & Clinics. Archived from the original on 10 May 2006.

Histrelin information

and 25 Related for: Histrelin information

Histrelin

Luteinizing hormone

Precocious puberty

Gonadotropin preparations

Menotropin

Leuprorelin

Human chorionic gonadotropin

Progonadotropin

Feminizing hormone therapy

Gonadorelin

ATC code L02

Puberty blocker

Transgender hormone therapy

Gonadotropin

Antigonadotropin

Goserelin

Urofollitropin

Androgen deprivation therapy

Triptorelin

Megestrol acetate

Relugolix

Vantas

Linzagolix

Deslorelin

California Proposition 65 list of chemicals